Read more

September 27, 2021
1 min read
Save

Top in cardiology: Benefits of chewing gum after surgery, updates in lipid research

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Recent data presented at the virtual Society of Thoracic Surgeons Perioperative and Critical Conference suggested that chewing gum may accelerate gut function among cardiac surgery patients. It was the top story in cardiology last week.

Another top story was about research on therapies that aim to reduce lipid-related risks. Christie M. Ballantyne, MD, FNLA, reviewed investigational therapies targeting lipoprotein(a) and triglyceride-lowering agents.

Operating room surgery
Source: Adobe Stock

Read these and more top stories in cardiology below:

Chewing gum after cardiac surgery may aid gut function

Chewing gum may aid in accelerating gut function among patients who received cardiac surgery, according to new data presented at the virtual Society of Thoracic Surgeons Perioperative and Critical Care Conference. Read more.

Novel agents targeting Lp(a), triglycerides spearhead profound change in therapies

Much research is being conducted on novel therapeutics to reduce residual lipid-related risks, a speaker said at the National Lipid Association Scientific Sessions. Read more.

Analysis: New labeling of sacubitril/valsartan could greatly expand eligible patients The new FDA labeling expansion of sacubitril/valsartan is positioned to increase the potential HF population eligible for the drug by up to 1.8 million individuals, according to a new analysis. Read more.

NLA issues new recommendations on lipid measurements in the management of CV

Accurate and precise laboratory lipid measurements are important. As such, the National Lipid Association has released a new scientific statement on lipid measurements in the management of CVDs. Read more.

Aficamten improves HF symptoms, hemodynamics at 10 weeks in obstructive HCM Aficamten, a novel selective cardiac myosin inhibitor, was associated with improvements in heart failure symptoms and hemodynamics at 10 weeks, according to a phase 2 study presented at the Heart Failure Society of America Annual Scientific Meeting. Read more.